We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Rapid Tests Conclusively Diagnose Chagas Disease

By LabMedica International staff writers
Posted on 19 Apr 2017
Chagas disease is caused by infection with the Trypanosoma cruzi that are generally transmitted by triatomine vectors that are endemic to the Americas. More...
It affects several million people and severe cardiac and/or digestive complications occur in about 30% of the chronically infected patients.

In recent decades, population movements from endemic to non-endemic regions and the chance of vector-independent transmission have globalized the disease impact to non-endemic countries like Spain. The acute stage of the disease is mostly asymptomatic and infection goes undiagnosed. In the chronic phase direct parasite detection is hampered due to its concealed presence and diagnosis is achieved by serological methods.

Scientists working with those at the Barcelona Institute for Global Health carried out a prospective study and took 342 blood samples from 223 women and 119 men living in an endemic region of Bolivia. Sampling was made between March and May 2014. The study was a double-blind with three different observers involved: two for each of the rapid diagnostic test (RDT), and a third one for the conventional serological tests (indirect hemagglutination assay (IHA), enzyme linked immunosorbent assays (ELISA), based on lysate antigen, and ELISA based on recombinant antigen.

The team used serodiagnosis, first by rapid screening with the RDT Chagas Stat-Pak. A second RDT, Chagas Detect Plus was also used in parallel. In order to qualify a rapidly diagnosed positive patient for treatment, conventional serological confirmation is obligatory. The ELISA tests were from Wiener Lab and included the parasite lysate-based ELISA.

The performance of CST and CDP was identical. The comparison with the conventional serology results yielded exactly the same results, either evaluating them individually or as a duo. Their reported sensitivity was 100% whereas specificity was 99.3%. RDTs positive predictive value was 99.5%, and their negative predictive value was 100%. In comparison with the three conventional serological tests, each RDT detected the same single false positive patient that was shown to be negative in all three conventional serology tests.

The authors concluded that their study validates the use of the CST and CDP diagnostic duo to reduce response time to patients and the logistic resources currently needed to elaborate a confirmed Chagas disease diagnosis. Therefore, they encourage considering the implementation of both RDTs with whole blood as sample to provide fast, reliable and definite diagnosis of Chagas disease in distant settings. The study was published on April 3, 2017, in the journal Public Library of Science Neglected Tropical Diseases.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Urinalysis Solution
UN-9000
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.